Standard BioTools Inc. reports developments in life-science research tools built around proprietary mass cytometry and microfluidics technologies. The company sells instruments, consumables and services for genomics, single-cell proteomics and spatial proteomics, including platforms such as Biomark X9, CyTOF XT and Hyperion systems used in research workflows.
Recurring news includes operating and financial results, capital-structure updates, shareholder voting and governance matters, portfolio actions following the completed sale of SomaLogic assets, and collaborations that expand imaging mass cytometry and multi-omic research applications. Company updates also describe translational and clinical research use cases in oncology, immunology and immunotherapy, with products positioned for research use rather than diagnostic procedures.
Standard BioTools (NASDAQ: LAB) will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.
Investors can expect a post-close release and likely an associated investor webcast or call timing to be announced separately by the company.
Standard BioTools (NASDAQ: LAB) completed the sale of SomaLogic to Illumina for $350 million upfront and is eligible for up to $75 million in near-term earnouts, for aggregate cash consideration of up to $425 million plus specified royalties.
As of Jan. 30, 2026, the company estimates approximately $550 million in cash and cash equivalents (unaudited), expects continuing operations to reach positive adjusted EBITDA in 2026, and retains a 2% royalty plus a co-exclusive Single SOMAmer license.
Standard BioTools (NASDAQ: LAB) announced preliminary, unaudited revenue for Q4 and full year 2025. The company expects Q4 2025 combined revenue of ~$56 million and revenue from continuing operations of ~$24 million. For full year 2025, it expects combined company revenue of ~$185 million and revenue from continuing operations of ~$85 million. Management said operational cost actions improved the operating model and moved the base business toward positive adjusted EBITDA. The sale of SomaLogic to Illumina is expected to close in H1 2026, and the company expects to have approximately $550 million in cash at close. Final audited results and 2026 outlook will be released later this quarter.
Molecular Instruments and Standard BioTools (NASDAQ: LAB) announced a collaboration on November 19, 2025 to integrate HCR imaging technologies with the Hyperion Imaging System to enable amplified multi-omic readouts for Imaging Mass Cytometry (IMC).
The partnership pairs HCR Gold for RNA and protein imaging and the HCR HiFi Encoder to permit direct protein encoding using any primary antibody, aiming to increase sensitivity for low-abundance markers and allow simultaneous high-fidelity RNA and protein spatial analysis in a single workflow. Joint development and early-access opportunities are underway.
Illumina (NASDAQ: ILMN) announced on Nov 10, 2025 that Illumina Protein Prep, commercially launched in September, is in use by more than 40 customers across 16 sites and has processed over 40,000 samples, offering a discovery panel of > 9,500 proteins at a claimed low cost per protein target.
Customers include Sydney Mass Spectrometry (first Asia Pacific site), Genomics England (reported a 7.5% increase in disease classification when integrating proteomics with genomics), and PRECISE-SG100K (running 10,000 plasma samples). Illumina also noted a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, subject to regulatory clearance.
Standard BioTools (NASDAQ: LAB) reported third quarter 2025 results for the quarter ended September 30, 2025, showing $19.6M revenue from continuing operations and $217.0M cash and equivalents on hand. Combined company revenue for Q3 was $46.2M. The company implemented an operational restructuring in September expected to deliver over $40M in annualized cost savings, and reiterated a target to reach positive adjusted EBITDA in 2026. Q3 continuing operations revenue declined 11% year-over-year with consumables down 17% and instruments down 3%. Gross margin from continuing operations was ~48.5% (non-GAAP 53.5%). Net loss from continuing operations was $31.7M and adjusted EBITDA loss was $16.5M. The company expects ~$550M in cash and equivalents at closing of the Illumina transaction in H1 2026 and maintained FY2025 combined revenue guidance of $165M–$175M.
Standard BioTools (NASDAQ: LAB) announced it will publish third quarter 2025 financial results on Tuesday, November 4, 2025.
The company said the results will be released after U.S. market close.
Illumina (NASDAQ:ILMN) has launched Illumina Protein Prep, a groundbreaking NGS-based proteomics assay capable of measuring 9,500 unique human protein targets. This launch follows the company's agreement to acquire SomaLogic, strengthening its position in the proteomics market.
The technology has demonstrated significant impact through early access programs, with 30,000 samples processed using the 6K assay and over 6,000 samples with the 9.5K assay. Notable success includes Genomics England's implementation in their 100,000 Genomes Project, which achieved a 7.5% increase in diagnostic yield for rare diseases.
The solution combines Illumina NovaSeq sequencing platforms with DRAGEN Protein Quantification and Connected Multiomics software, enabling researchers to streamline analysis from discovery to therapeutic development. The company has also announced a pilot program with UK Biobank to analyze 50,000 samples using this technology.
Standard BioTools (NASDAQ:LAB) reported Q2 2025 financial results, highlighting a strategic transformation with the sale of SomaLogic to Illumina for up to $425 million in cash plus future royalties. Q2 revenue from continuing operations was $21.8 million, down 3% year-over-year. The company reported $240 million in cash and expects at least $550 million post-Illumina transaction closure.
Key metrics include consumables revenue of $10.5 million (up 18% YoY), instruments revenue of $5.2 million (down 26% YoY), and services revenue of $6.1 million (down 8% YoY). The company improved its net loss to $17.7 million from $25.4 million in Q2 2024. For FY2025, Standard BioTools expects combined revenue of $165-175 million, with continuing operations revenue of $78-83 million.
Standard BioTools (NASDAQ:LAB) announced that PRECISE-SG100K has selected their SomaScan 11K Assay to analyze 100,000 plasma samples from their biobank after evaluating competitive proteomics platforms.
The collaboration represents one of the world's largest population health research studies, leveraging Singapore's multi-ethnic population. Standard BioTools' SomaScan platform was chosen for its superior proteome coverage, reproducibility, and service quality. The company has established itself as a leader in population proteomics, with SomaScan being used in over 30 biobank studies globally, including three major additions this year totaling nearly 160,000 samples.